A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells

Shroff, Geeta

doi:10.2147/sccaa.s135415

Cited by 32 publications

(28 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 Because of the success of these treatments as well as the theoretically limitless growth potential of stem cells, stem cells have become the new frontier for the treatment of a variety of chronic conditions. 41,42 For example, stem cells are now being investigated for their potential to treat degenerative diseases, such as multiple sclerosis, 43 Parkinson's disease 44 or myocardial ischemia. 45 Despite the fact that many theoretical models for these treatments have been developed, none have yet been translated into routine clinical care.…”

Section: Discussionmentioning

confidence: 99%

<p>Informatics Approaches for Harmonized Intelligent Integration of Stem Cell Research</p>

Finkelstein

Parvanova

Zhang

2020

SCCAA

View full text Add to dashboard Cite

As biomedical data integration and analytics play an increasing role in the field of stem cell research, it becomes important to develop ways to standardize, aggregate, and share data among researchers. For this reason, many databases have been developed in recent years in an attempt to systematically warehouse data from different stem cell projects and experiments at the same time. However, these databases vary widely in their implementation and structure. The aim of this scoping review is to characterize the main features of available stem cell databases in order to identify specifications useful for implementation in future stem cell databases. We conducted a scoping review of peer-reviewed literature and online resources to identify and review available stem cell databases. To identify the relevant databases, we performed a PubMed search using relevant MeSH terms followed by a web search for databases which may not have an associated journal article. In total, we identified 16 databases to include in this review. The data elements reported in these databases represented a broad spectrum of parameters from basic socio-demographic variables to various cells characteristics, cell surface markers expression, and clinical trial results. Three broad sets of functional features that provide utility for future stem cell research and facilitate bioinformatics workflows were identified. These features consisted of the following: common data elements, data visualization and analysis tools, and biomedical ontologies for data integration. Stem cell bioinformatics is a quickly evolving field that generates a growing number of heterogeneous data sets. Further progress in the stem cell research may be greatly facilitated by development of applications for intelligent stem cell data aggregation, sharing and collaboration process.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Informatics Approaches for Harmonized Intelligent Integration of Stem Cell Research</p>

Finkelstein

Parvanova

Zhang

2020

SCCAA

View full text Add to dashboard Cite

show abstract

“…Unfortunately, there is no effective therapeutic method for MS disease and current medications can only manage and relieve the progress of the disease but not treat it thoroughly. Recent investigations have shown that cell-based therapies are able to repair CNS and can protect it against inflammatory responses caused by immune system (65). Cell-based therapies have provided a new window for the prevention and treatment of different neurodegenerative diseases such as MS, Parkinson's disease (PD), Alzheimer's and amyotrophic lateral sclerosis (ALS).…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis

et al. 2019

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a multifocal inflammatory disease that involves the central nervous system and associated with limbs paralysis and serious problems in sensation, limbs, visual and sphincter. This disease is a result of autoimmune mechanism in which autoantibodies target the self-myelin antigens and cause demyelination. Because of the myelin dysfunction, MS is clinically identified with neurological disabilities. Furthermore, it can be entered into the progressive phase because of irreversible neurodegeneration and axons damage. Unfortunately, there is no effective therapeutic method for this disease and current medications have been focused on amelioration of symptoms and chronic inflammation.Although current immunotherapies ameliorate the reactivity of autoimmune anti-myelin and MS relapse rate, there is no approved method for improvement of the disease progression and repairing of the damaged myelin. Therefore, finding an appropriate clinical treatment for improvement of neurological damages in MS patients is essential. Mesenchymal stem cells (MSCs) are multipotent cells with high proliferative and self-renewal capacities, as well as immunomodulatory and neuroregenerative effects. Bone marrow and adipose tissues derived MSCs have been considered for the treatment of different diseases because not only they can be easily isolated from these tissues, but also a patient can be served as a donor for himself without the risk of rejection. More importantly, autologous MSCs carry a safer pattern without the risk of malignant transformation. Here, we will discuss the effectiveness of MSCs therapy for MS patients by reviewing of clinical trials.

show abstract

“…Stem cells showed itself as an effective therapy in regeneration medicine and a novel approach to prevail on the limitations of presently existing MS management. Stem cell use is now available all over the world to treat MS [39]. Neural precursor stem cells provide a source of remyelinating cells with the ability to structurally repair the central nervous system [40].…”

Section: Organ Specific Cell Therapymentioning

confidence: 99%

Immunomodulating, Neuroprotective and Regenerative Modalities in Multiple Sclerosis Management

KS¹,

Michele²,

Dina³

et al. 2020

Int J Neurodegener Dis

View full text Add to dashboard Cite

The incidence of Multiple sclerosis disease is rapidly increasing worldwide, for instance, across Asia, the utmost growth was confirmed in Japan from 1,000 in 1980 to more than 20,000 people in 2019 [1]. The phenomenon of "Westernization" in Asian countries which includes a specific choice of food and lifestyle was related to the higher prevalence of MS in Asia's population which almost supports new findings on the great influence of gut and its microbiota in people worldwide. The current conventional therapy helps to prolong the periods between attacks and relapses, but in fact, does not slow down the disease progression and impact on physical activities which eventually leads to disabilities. The development of a new approach and data is highly required with the opportunity to avoid immunity suppression. This review article shares information on the complex integrative approach of the management of MS cases with the application of immune-modulating peptides, mitochondria derived neural peptides, precursor stem cells, active specific immunotherapy therapy and diet. The results showed a regeneration effect, stable prolonged remission, a reversal of symptoms, reduction of side effects, high efficacy of reduction of MS lesions as well as safety of combination (ongoing and integrative) approach. RevieW ARTiCLe Check for updates people who live with MS are more than 2.3 million [3], a debilitating condition triggered by an autoimmune response that causes inflammation damage to nerve cells in the central nervous system and currently incurable. MS is highly often diagnosed in females than males about 2 to 3 times more common in relapsing-remitting MS [4]. This phenomenon also shared with several other autoimmune diseases, like rheumatoid arthritis. MS most commonly affects people between the ages of 20 and 50 years and also might be presented in childhood or late middle age [5]. Researchers have found that MS affects different age groups differently. For instance, people who are diagnosed when they are 50 years or older typically have a more progressive disease course. MS is determined as a chronic inflammatory disease of the brain and spinal cord with focal lymphocytic infiltration, which eventually harms myelin sheaths and axons [6]. Primarily, inflammation is temporal, and remyelination happens but is not permanent, and as such, the early stages of MS are presented by incidences of neurological dysfunction, which is next followed by recovery [7]. Anyway, after some time, the pathological changes become inevitable and constant by proliferation microglial activation related to comprehensive and chronic neurodegeneration which clinically appear as a progressive accumulation of disability [8].

show abstract

A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells

Cited by 32 publications

References 83 publications

<p>Informatics Approaches for Harmonized Intelligent Integration of Stem Cell Research</p>

<p>Informatics Approaches for Harmonized Intelligent Integration of Stem Cell Research</p>

Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis

Immunomodulating, Neuroprotective and Regenerative Modalities in Multiple Sclerosis Management

Contact Info

Product

Resources

About